
Drug master file (DMF): types, letter of authorization, GDUFA fee and what FDA finds at API facilities
What a drug master file is under 21 CFR 314.420, the four DMF types still open (II, III, IV and V; Type I was removed in 2000), how a letter of authorization lets an ANDA, NDA or IND reference the file, the GDUFA Type II API DMF fee and initial completeness assessment, and why FDA inspects the DMF holder's facility. Ends with Atlas data on API manufacturers: 47 Form 483s at registered API facilities from January 2025 to July 2026, API warning letters by year since 2021, and the inspection record of six API facilities that received letters in 2025 and 2026.


















